Therefore, EGFR is a widely accepted therapeutic target, either using small molecule tyrosine kinase inhibitors (e.g., erlotinib in lung adenocarcinoma) or blocking antibody (e.g., cetuximab in HNSCC). The gene discussed is EGFR; the disease is lung adenocarcinoma.